SomaLogic, Inc. (SLGC): Price and Financial Metrics

SomaLogic, Inc. (SLGC): $9.31

-0.01 (-0.11%)

POWR Rating

Component Grades













SLGC Stock Price Chart Interactive Chart >

Price chart for SLGC

SLGC Price/Volume Stats

Current price $9.31 52-week high $14.72
Prev. close $9.32 52-week low $8.83
Day low $8.83 Volume 565,100
Day high $9.42 Avg. volume 1,001,760
50-day MA $11.69 Dividend yield N/A
200-day MA $0.00 Market Cap 1.69B

SomaLogic, Inc. (SLGC) Company Bio

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow-offrate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company's solutions also include SomaSignal tests, which are research use only tests for clinical trial applications. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions; and facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.

SLGC Latest News Stream

Event/Time News Detail
Loading, please wait...

SLGC Latest Social Stream

Loading social stream, please wait...

View Full SLGC Social Stream

Latest SLGC News From Around the Web

Below are the latest news stories about SomaLogic Inc that investors may wish to consider to help them evaluate SLGC as an investment opportunity.

SomaLogic (SLGC) Presents At 40th Annual J.P. Morgan Healthcare Conference - Slideshow

The following slide deck was published by SomaLogic, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | January 11, 2022

SomaLogic Announces Preliminary Revenue for Full Year 2021 Above Guidance Range

Presenting at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 8:15 a.m. Eastern TimeBOULDER, Colo., Jan. 11, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced preliminary, unaudited revenue expectations for the year ending December 31st, 2021. Preliminary, unaudited revenue for the full year 2021 is expected to exceed $79 million, the upper end of SomaLogic’s previously raised 2021 revenue guidance range

Yahoo | January 11, 2022

SomaLogic Announces Appointment of Adam Taich as Chief Business Officer

BOULDER, Colo., Jan. 10, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced that Adam Taich has joined the company as the Chief Business Officer. In this newly created role, Adam will have broad responsibility across SomaLogic’s rapidly growing business to drive the company’s strategic and business development goals. He will also serve as a member of SomaLogic’s Executive Committee. Adam will report to SomaLogic Chief Executive Offic

Yahoo | January 10, 2022

SomaLogic Announces Analyst and Investor Meeting on February 4, 2022

BOULDER, Colo., Jan. 07, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, will host a virtual Analyst and Investor Meeting on Friday, February 4, 2022, beginning at 10:00 a.m. Eastern Time. The virtual event will feature presentations from company leaders outlining SomaLogic’s unique positioning in proteomics, financial profile, and plans for continued business evolution and growth as the company furthers its scientific and commercial progress. The even

Yahoo | January 7, 2022

SomaLogic announces exclusive partnership with Illumina to develop sequencing-based proteomic solutions

Co-developed and co-branded products to combine market-leading proteomic and genomic analysis platformsBOULDER, Colo., Jan. 05, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced a worldwide strategic collaboration with Illumina, a global next-generation sequencing technology leader. The multi-year partnership agreement will bring together genomics and proteomics technology platforms in a major commercial partnership to better enable

Yahoo | January 5, 2022

Read More 'SLGC' Stories Here

SLGC Price Returns

1-mo -14.43%
3-mo -19.67%
6-mo -19.18%
1-year N/A
3-year N/A
5-year N/A
YTD -20.02%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6441 seconds.